|
GB202101848D0
|
|
Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
|
|
WO2021018750A1
|
|
Ophthalmic compositions comprising viscosifying polymers and nucleic acids
|
|
GB202011428D0
|
|
Antisense oligonucleotides for RNA editing
|
|
WO2020254249A1
|
|
Delivery of nucleic acids for the treatment of auditory disorders
|
|
WO2020252376A1
|
|
Antisense rna editing oligonucleotides comprising cytidine analogs
|
|
WO2020212567A1
|
|
Antisense oligonucleotides for the treatment of usher syndrome
|
|
WO2020201144A1
|
|
Antisense oligonucleotides for immunotherapy
|
|
WO2020157014A1
|
|
Antisense oligonucleotides for the treatment of leber's congenital amaurosis
|
|
WO2020157008A1
|
|
Rna-editing oligonucleotides for the treatment of usher syndrome
|
|
GB201908441D0
|
|
Antisense oligonucleotides for immunotherapy
|
|
GB201905732D0
|
|
RNA editing inhibitors and methods of use
|
|
GB201904709D0
|
|
Chemically modified oligonucleotides
|
|
GB201904647D0
|
|
Antisense oligonucleotides for immunotherapy
|
|
GB201902735D0
|
|
Oligonucleotides for use in the treatment of dystrophic epidermolysis bullosa
|
|
GB201901873D0
|
|
Antisense oligonucleotides for nucleic acid editing
|
|
US2021079393A1
|
|
Antisense oligonucleotides for rna editing
|
|
GB201815781D0
|
|
Antisense oligonucleotides for RNA editing
|
|
GB201808146D0
|
|
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
GB201807387D0
|
|
Stereospecific linkages in rna editing oligonucleotides
|
|
GB201802392D0
|
|
Antisense oligonucleotides for RNA editing
|
